Abstract PS14-09: Central Nervous System as the Primary Site of First Relapse in Patients with Triple-Negative Breast Cancer Achieving Pathological Complete Response After Neoadjuvant Treatment
Davide Massa(University of Padua), Maria Vittoria Dieci(University of Padua), Federica Miglietta(University of Padua), Luisa Carbognin(Agostino Gemelli University Polyclinic), Sylvie Giacchetti, Giacomo Mazzoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Emilio Bria(Università Cattolica del Sacro Cuore), Marina La Commare, Valentina Guarneri(Istituto Oncologico Veneto), Andrea Botticelli(Sapienza University of Rome), Clémentine Bouchez, Carmen Criscitiello(University of Milan), Marleen Kok(The Netherlands Cancer Institute), Giulio Martinelli, Esther H. Lips(Oncode Institute), Moira Ragazzi(Santa Maria Nuova Hospital), Giorgio Bonomi(University of Padua), Elisa Gasparini(Azienda Sanitaria Unità Locale di Reggio Emilia), Giuseppe Fotia, Gaia Griguolo(University of North Carolina at Chapel Hill), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), D. Napetti(University of Padua), Laetitia Someil, Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 0
Related Papers
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
|Nature Medicine|2019|878
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413